Results 201 to 210 of about 155,399 (295)

Unveiling protective mechanisms of wild olive (acebuche) oil in retinal pigment epithelial cells with hypertensive phenotype

The Journal of Physiology, EarlyView.
Abstract figure legend Circulating extracellular vesicles (EVs) derived from acebuche (ACE) oil‐ and extra virgin olive oil (EVOO)‐fed mice modulate nitric oxide (NO) metabolism in the retinal pigment epithelial cell line (ARPE19) with a hypertensive phenotype induced by angiotensin II (AngII).
Álvaro Santana‐Garrido, Claudia Reyes‐Goya, Pablo Espinosa‐Martín, Rosa M. Troya‐Toledo, Helder André, Alfonso Mate, Carmen M. Vázquez   +6 more
wiley   +1 more source

Therapeutic potential of taurine in a pigmented rat model of age-related macular degeneration. [PDF]

Front Ophthalmol (Lausanne)
Attia M, Pavlovic T, Muliawan A, Tuya F, Mihalatos M, Iwanicki M, Kang-Mieler J.   +6 more
europepmc   +1 more source

TLR4 inhibitor attenuates amyloid-β-induced angiogenic and inflammatory factors in ARPE-19 cells: Implications for age-related macular degeneration

, 2016
Li Chen, Yujing Bai, Min Zhao, Yanrong Jiang   +3 more
openalex   +2 more sources

Incidence of Retinal Pigment Epithelial Tears and Associated Risk Factors After Treatment of Age-Related Macular Degeneration with Intravitreal Anti-VEGF Injections§ [PDF]

, 2014
Theodoros Empeslidis, Athanasios Vardarinos, Vasileios Konidaris, Soon Wai Ch’ng, Bharat Kapoor, James Deane, Konstantinos T. Tsaousis   +6 more
openalex   +1 more source

Implantable Drug Delivery Systems for Skeletal Muscles and Eyes

Advanced NanoBiomed Research, Volume 6, Issue 2, February 2026.
This review highlights the different types of recent implantable drug delivery systems (IDDS) fabricated for a use with skeletal muscles, and with eyes. It presents the developments already made and the current research directions, showing the evolution of IDDS and their great diversity.
Serge Ostrovidov, Murugan Ramalingam, Hongkai Wu, Toshinori Fujie, Yukinari Nakamura, Takeshi Hori, Yuji Nashimoto, Xuetao Shi, Hirokazu Kaji   +8 more
wiley   +1 more source

Efficacy and Safety of Intravitreal Faricimab in Age-Related Macular Degeneration-A Review. [PDF]

J Clin Med
Chan CC, Liu PK, Cheng KC, Lai HC, Chang YC.   +4 more
europepmc   +1 more source

Ana S. Falcão, Margarida Pedro, Luisa de Lemos, Shuvajit Rakshit, Pedro Antas, Sandra Tenreiro and Miguel C. Seabra*. A preclinical approach to explore the NRF2 pathway as a therapeutic strategy in age-related macular degeneration. 8th BenBedPhar Meeting, themed "Thirty years since the discovery of NRF2", October 10-12, 2024, Lisbon, Portugal

Falcao, Ana
openalex   +1 more source

Availability, use, efficacy and safety of bevacizumab in European hereditary haemorrhagic telangiectasia centres

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 535-544, February 2026.
Introduction Bevacizumab, a vascular endothelial growth factor inhibitor, is used off‐label for treatment of severe anaemia related to epistaxis, gastrointestinal bleeding and/or severe hepatic arteriovenous malformations (HAVM) and right‐sided cardiac failure in patients with hereditary haemorrhagic telangiectasia (HHT).
Pernille D. Haahr, Anette D. Kjeldsen, Annette D. Fialla, Anne‐Emmanuelle Fargeton, Alexandre Guilhem, Elisabetta Buscarini, Freya Droege, Guido Manfredi, Hans‐Jurgen Mager, Jean‐Christophe Saurin, Jens Kjeldsen, Josefien Hessels, Marco C. Post, Robert Mandic, Sanne Boerman, Stefan Kasper‐Virchow, Sören Möller, Urban Geisthoff, Sophie Dupuis‐Girod   +18 more
wiley   +1 more source

Therapeutic effects of various therapeutic strategies on non-exudative age-related macular degeneration

, 2018
Yanli Wei, Hongxia Liao, Jian Ye
openalex   +1 more source

Comorbidities at MS Diagnosis and Their Association With Treatment Persistence: Real‐World Clinical Data

Brain and Behavior, Volume 16, Issue 2, February 2026.
Comorbidity was present in approximately half of the patients with relapsing‐remitting multiple sclerosis in this Finnish cross‐sectional cohort. Comorbidities, especially psychiatric diseases, were associated with lower persistence on injectable disease‐modifying treatments.
Henrik Ahvenjärvi, Ida Lund, Anne M. Portaankorva, Johanna Krüger, Mervi Ryytty   +4 more
wiley   +1 more source